Canadian Cardiovascular Society
 
Canadian Cardiovascular Society

Cardiorenal Risk Reduction (2022)

CJC Publication & Download
Citation

Guideline Table of Contents

Abstract
Introduction
1. SGLT2i for the Treatment of HF
2. Integration of SGLT2i in the Management of Patients With CKD
3. Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD
4. Practical Considerations for Integrating GLP-1RA and SGLT2i Into Practice
5. Summary and Conclusions

Guidelines

Back to top